Ramosetron hydrochloride for the prevention of cancer chemotherapy induced nausea and vomiting: The Indian experience

BACKGROUND: Despite the advent of 5-HT(3) antagonists, control of delayed gastrointestinal adverse events with cancer chemotherapy is still not optimal. This open label, active controlled, multicentric clinical trial was undertaken to assess the comparative efficacy and safety of ramosetron with ond...

Descripción completa

Detalles Bibliográficos
Autores principales: Sanmukhani, Jayesh J., Pawar, Prafulla, Mittal, Ravindra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2014
Materias:
SOUTH ASIAN UPDATE: Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4014645/
https://www.ncbi.nlm.nih.gov/pubmed/24818110
http://dx.doi.org/10.4103/2278-330X.130466

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4014645/
https://www.ncbi.nlm.nih.gov/pubmed/24818110
http://dx.doi.org/10.4103/2278-330X.130466

Ejemplares similares